Large Cancer Panel Test
Finland · Vantaa · how to bid here →
Your path to submission
- Deadline: 14 September at 00:00 — 6 days left.
- You submit on Hilma — not here and not by e-mail. ↗
- Offer and evidence in: ENG, ENG.
- Collect your evidence — the eligibility requirements are listed above; for many of them the analysis explains how to obtain them.
Clement What the numbers say about this buyer
- In this sector the buyer awards roughly every 2 months (25 awards, most recently July 2026) — the next award is due around September 2026 by that rhythm. The last award went to Ortus Medical ApS.n = 25
- 30% of awards went to companies from abroad (37 awards with a known winner country). Sector average: 4%.n = 37
- 28% of this buyer's awards went to companies that had already won here before (37 awards since 2023, spread over 26 companies). That is well below the sector norm (49%) — this buyer switches suppliers more often than others.n = 37 awards since 2023
- The median procedure drew 2 bids (9 procedures with a bid count); 33% ended with a single bidder. Sector: median 4 bids.n = 9
- The award came in at a median 100% of the estimated value (5 awards with both estimate and value) — pricing at the estimate is usually about right here. Sector: 100%.n = 5
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 07/09/2026.
Foreign bidders
In Finland · Medical equipment & pharma, 203 contracts went to foreign companies over the last 3 years (of 6,718 recorded awards) — mostly from Germany, Sweden, Denmark.
Typical field: median 2 (from 8 awards).
What the buyer is looking for
The HUS Group (also "the contracting entity", "the Client" or “HUS”) requests tenders for a large cancer panel test for HUS Diagnostic Center. The procurement includes also data analysis software for reporting clinically significant variants, copy number alterations and gene fusions. The software can be offered by the same provider as the large cancer panel test or from a partner company (offer as a group or appeal to a subcontractor's resources), but it needs to be included in the same tender. The software will be procured for the entire lifecycle of the assay. The procurement consist of gene panels and reagents (also "products") and data analysis software (also "services", e.g. information system provided as Software as a Service). Laboratory of Genetics at HUS (Helsinki University Hospital) Diagnostic Center is an SFS-EN ISO 15189:2022 accredited laboratory providing diagnostic…
Show full description
… genetic testing services to all patients at Helsinki and Uusimaa Hospital District. The laboratory operates as a health institution capable of validating in-house developed tests as required by the CE-IVD regulation. The services include analysis of both constitutional samples and malignancies. The laboratory provides sequencing services mainly using local sequencing capacity (Illumina NovaSeq 6000, NovaSeq X Plus, Ion GeneStudio S5 Prime equipment). The large cancer panel test is intended for detection of small nucleotide variants (SNVs), indels, gene fusions, copy number variations (CNVs), microsatellite instability (MSI), homologous recombination deficiency (HRD), and tumor mutation burden (TMB) relevant for the genetic profiling of solid tumor samples and/or hematological malignancies as well as plasma samples for cfDNA analysis. Sequencing of the samples is carried out using Illumina NovaSeq sequencers (Illumina NovaSeq 6000 and NovaSeq X Plus). The number of cancer panel tests performed annually is estimated to be between 2500-3000. The procurement is divided into LOT A and LOT B: LOT A - This lot includes gene panel solutions for in-house NGS testing of solid tumors and hematological malignancies, including library preparation reagents, target enrichment reagents defining the panel content, panel-specific reagents, data analysis software, and instructions for use. Sequencing reagents, flow cells, sequencing instruments, and testing services are not included in this procurement. - This test is based on analysis of total nucleic acids (RNA and/or DNA) extracted from paraffin embedded specimens and/or fresh-frozen specimens - This lot includes an option for special gene panel and reagents for salivary gland tumors with data analysis software - This lot includes an an option for a custom gene panel and reagents with data analysis software - The HUS Group will decide separately on the use of the options LOT B Important Information Concerning Lot B of the Procurement Procedure The Contracting Authority has decided to discontinue Lot B of the procurement procedure.During the procurement procedure, it became apparent that substantial amendments are required to the subject matter of Lot B and the related procurement documents. As these amendments cannot be implemented through a corrigendum without jeopardising the equal and non-discriminatory treatment of tenderers, the Contracting Authority has decided to discontinue Lot B.Lot B will be re-tendered through a separate procurement procedure. A new contract notice and new procurement documents for Lot B will be published separately.Please note that LOT A is still continuing the tendering process. - This lot includes gene panel solutions for in-house NGS testing of cell-free DNA, including library preparation reagents, target enrichment reagents defining the panel content, panel-specific reagents, data analysis software, and instructions for use. Sequencing reagents, flow cells, sequencing instruments, and testing services are not included in this procurement - This test is based on analysis of cell-free
Selection criteria — in the procurement documents
The buyer states in the notice that the selection criteria are in the procurement documents (link on the right), not in the EU form. The document analysis below extracts them from there — bid and evidence in ENG, ENG.
Contract
Who has won here before
| Company | Awards | Period |
|---|---|---|
| Roche diagnostics Oy | 3 | 2023–2026 |
| Fresenius Kabi Ab | 2 | 2024 |
| B. Braun Medical Oy (0111467-5)//Fresenius Kabi Ab | 2 | 2024 |
| SJJ Solutions B.V. | 2 | 2025 |
| Medicolle AB | 2 | 2025 |
How often this buyer tenders this
Who knows the rhythm prepares instead of reacting.